Integra LifeSciences (IART) to Release Earnings on Tuesday

Integra LifeSciences (NASDAQ:IART) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Integra LifeSciences to post earnings of $0.42 per share and revenue of $381.81 million for the quarter. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same period last year, the firm posted $0.97 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $10.69 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average price of $10.18 and a two-hundred day moving average price of $11.80. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $17.54. The company has a market capitalization of $833.18 million, a P/E ratio of -1.59 and a beta of 1.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IART. Global Retirement Partners LLC acquired a new position in Integra LifeSciences during the fourth quarter valued at approximately $25,000. Osaic Holdings Inc. lifted its position in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares in the last quarter. Virtu Financial LLC acquired a new position in Integra LifeSciences during the fourth quarter valued at approximately $124,000. Finally, Amundi lifted its position in shares of Integra LifeSciences by 17,193.8% during the second quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after purchasing an additional 11,004 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent research reports. Wells Fargo & Company upgraded shares of Integra LifeSciences to a “hold” rating in a report on Wednesday, March 18th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Citigroup decreased their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Finally, Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $14.20.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.